Migraine With Aura and Stroke Risk in Men. What the Vascular Evidence Shows.

He is forty-four years old and has had migraines his entire adult life. He knows the warning signs: the shimmering arc that appears at the edge of his left visual field, spreading slowly across his vision over fifteen to twenty minutes, then fading before the headache arrives. He has been told these are migraines. He takes an over-the-counter pain reliever and waits. His neurologist documented “migraine with aura” in his chart eight years ago. His cardiologist has never asked about it. His internist, if pressed, would say that migraines are a headache problem, not a heart problem, and that the connection to stroke risk exists mainly in women who take oral contraceptives.

All of that framing is incomplete. The visual disturbance this man experiences before his headaches is not simply a neurological inconvenience. It is a marker of cerebrovascular and cardiovascular vulnerability that places him in a meaningfully different risk category than a man with migraine without aura. Understanding why requires stepping through the vascular biology of migraine aura, what epidemiology has documented about the stroke relationship in men, and what other risk factors compound the picture in ways that his current care may not be systematically addressing.

What Migraine With Aura Actually Is

The distinction between migraine with aura and migraine without aura is not simply a question of symptom complexity. It represents a different pathophysiological process with different vascular implications. Migraine without aura, the more common form, is predominantly a headache disorder driven by trigeminovascular activation and neuropeptide release, with neurovascular changes that are largely confined to the headache phase itself. Migraine with aura involves an additional preceding cortical event that has distinct vascular consequences.

Aura is the clinical expression of cortical spreading depression, first described by the physiologist Leao in 1944 as a slow wave of neuronal and glial depolarization that propagates across the cortical surface at approximately 3 to 5 millimeters per minute. The visual aura that most people associate with migraine, the shimmering zigzag arc called a scintillating scotoma, reflects this wave moving across the visual cortex. As it passes, it produces a transient zone of neuronal silence followed by depolarization, which maps to the visual disturbance. The wave moves too slowly and too regularly to be confused with a focal seizure, and it extinguishes on its own as it reaches cortical boundaries.

The vascular consequences of cortical spreading depression are what separate migraine with aura from a purely neurological event. As the depolarization wave passes, it causes a brief initial dilation of cortical vessels followed by sustained oligemia: a period of significantly reduced cortical blood flow that outlasts the aura symptoms and, in some individuals, persists for up to an hour after aura resolution. This oligemic phase is distinct from the hypoperfusion that would produce an infarct in most circumstances, because it typically resolves and because the neuronal tissue remains viable. But it creates a window of vascular vulnerability, and it involves vascular mechanisms that are relevant to the stroke risk question: endothelial activation, platelet activation, and transient perfusion changes in tissue that depends on tight autoregulatory control.

The Epidemiology of Migraine, Aura, and Stroke in Men

The epidemiological relationship between migraine with aura and ischemic stroke has been documented across multiple large prospective cohort studies and meta-analyses. The central finding is consistent: migraine with aura approximately doubles the risk of ischemic stroke compared to individuals without migraine. The finding holds after adjustment for conventional stroke risk factors including hypertension, smoking, diabetes, and hyperlipidemia.

Kurth and colleagues published a meta-analysis in the British Medical Journal that pooled individual patient data from over 388,000 participants across eleven studies, examining the association between migraine and stroke. (Kurth et al., BMJ 2009) 5 / Solid The pooled relative risk for ischemic stroke in individuals with migraine with aura was 2.16 compared to controls without migraine. The relationship was present in both sexes, and while the relative risk appeared somewhat higher in women, the risk in men was statistically significant and clinically meaningful. Men with migraine with aura had more than twice the ischemic stroke risk of men without migraine, independent of other vascular risk factors.

This requires careful framing. The relative risk is real, and doubling a risk is not a negligible finding. But the absolute baseline ischemic stroke risk in a man in his forties without other major vascular risk factors is low, typically expressed as fewer than 1 to 2 events per 1,000 person-years. Doubling a small absolute risk produces a risk that remains small in absolute terms. The clinical importance of the migraine-with-aura stroke association lies not in its power to predict imminent stroke in an otherwise healthy young man, but in two other considerations: it is a signal of underlying cerebrovascular vulnerability that compounds with other risk factors, and it identifies a patient population that should be managed with particular attention to modifiable stroke and cardiovascular risk factors because the baseline is already higher than in their migraine-free peers.

The Physicians Health Study, a large prospective cohort of male physicians followed for over ten years, provided data specifically on men and migraine. Male physicians with migraine with aura had a significantly higher risk of major cardiovascular events compared to those without migraine, including not just stroke but cardiovascular mortality and myocardial infarction. (Kurth et al., Arch Intern Med 2006) 5 / Solid This is an important finding for clinical practice in men: migraine with aura is not solely a cerebrovascular risk marker. It appears to signal systemic vascular vulnerability that extends to coronary risk as well.

Why Aura Specifically and Not Just Migraine

The specificity of the stroke and cardiovascular association to migraine with aura rather than to migraine overall is one of the more important distinctions in this literature and one that is frequently blurred in clinical communication. Men who have migraine without aura carry a different risk profile than men with aura, and conflating the two produces a distorted picture.

Multiple analyses have confirmed that the stroke risk elevation observed in migraine patients is primarily driven by the aura subgroup. Schurks and colleagues conducted a meta-analysis examining migraine subtypes and vascular events, finding that migraine without aura did not carry a statistically significant independent stroke risk, while migraine with aura was associated with a relative risk of approximately 2.0 for ischemic stroke. (Schurks et al., BMJ 2009) 5 / Solid This distinction matters clinically. A man presenting to a cardiologist or internist with a diagnosis of “migraine” needs a more specific characterization: does he have aura or not? That question determines whether his headache history belongs in a comprehensive cardiovascular risk assessment or whether it can be addressed primarily as a neurology management concern.

The biological reasons for the aura-specific risk are not fully established, but several mechanisms are supported by evidence and converge toward a coherent picture.

Proposed Mechanisms Linking Aura to Vascular Risk

Cortical spreading depression and endothelial dysfunction

Cortical spreading depression does not confine its vascular effects to the local cerebral cortex during an acute episode. Research has identified that CSD activates trigeminal afferents that project to dural vessels, triggering the release of neuropeptides including calcitonin gene-related peptide and substance P. These neuropeptides produce neurogenic inflammation in dural and pial vessels and, at higher frequencies or over longer time periods, may contribute to systemic endothelial activation. Circulating markers of endothelial dysfunction are elevated in migraine with aura patients compared to controls without migraine, suggesting that the condition involves ongoing vascular wall changes that are not limited to the acute episode. (Tietjen et al., Cephalalgia 2012) 4 / Promising Endothelial dysfunction is a recognized early step in atherogenesis and is associated with impaired vasodilation response, increased thrombotic potential, and accelerated plaque development.

Platelet activation

Several studies have documented abnormal platelet aggregation in migraine with aura patients outside of acute attacks, suggesting that platelet activation may be a persistent phenotype rather than simply an acute-phase phenomenon. Activated platelets release serotonin and thromboxane A2, both of which promote vasoconstriction and thrombus formation. In the context of vascular beds that are already subject to transient perfusion changes from cortical spreading depression, circulating platelet activation represents an additional thrombotic input. The evidence here is more mechanistic than directly outcome-linked, and it represents a plausible contributing pathway rather than a fully established causal mechanism. 3 / Early

Patent foramen ovale and paradoxical embolism

The prevalence of patent foramen ovale in the general adult population is approximately 25 to 30 percent. In migraine with aura patients, multiple studies have reported higher prevalence of PFO, with some case-control studies finding PFO in 40 to 50 percent of migraine with aura subjects. (Schwedt et al., Circulation 2008) 4 / Promising This association is controversial because it is bidirectional in interpretation: does PFO cause migraine with aura through microembolic mechanisms, or do the two conditions share a common developmental predisposition? The clinical significance is that a man with migraine with aura and a PFO has a mechanism for paradoxical embolism: small venous thrombi, which would normally be filtered by the pulmonary circulation, can traverse the atrial septal opening and enter the systemic arterial circulation, where they can reach the cerebral vasculature and produce cryptogenic stroke.

In men with cryptogenic stroke and migraine with aura, the co-presence of PFO shifts the probability distribution of stroke etiology meaningfully, and this has implications for how a cardiologist approaches workup and subsequent management conversation. Whether PFO closure in this population reduces migraine frequency or recurrent stroke risk remains an active area of investigation, and the evidence base is evolving.

Subclinical white matter changes

Neuroimaging studies have documented a higher prevalence of subclinical white matter hyperintensities in migraine with aura patients compared to age-matched controls. These lesions, visible on MRI as small areas of increased signal in the cerebral white matter, are markers of small vessel disease and are associated with cognitive risk and vascular vulnerability over time. The Rotterdam Study, a large longitudinal population study, found that women with migraine with aura had significantly higher burden of white matter lesions than controls; subsequent work has documented similar patterns in men, though the magnitude of the sex-specific finding has varied across studies. (Kruit et al., JAMA 2004) 4 / Promising These lesions likely reflect prior microembolic events, ischemic injury from the oligemic phases of aura, or chronic vasoreactive changes in the microcirculation, and they provide imaging evidence that the vascular burden of migraine with aura extends beyond what is visible clinically.

Risk Factors That Compound the Picture

The doubled relative stroke risk in men with migraine with aura is a baseline finding in the absence of other major risk factors. The clinical importance escalates substantially when migraine with aura co-occurs with additional vascular risk factors, because the risks are not necessarily simply additive.

Hypertension is the most important compounding factor. Hypertension independently doubles the stroke risk, and its combination with migraine with aura has been shown to produce risk estimates considerably above what either condition produces alone. Men with migraine with aura should have their blood pressure managed with particular attentiveness, not treated to general population targets with the migraine noted as a separate neurology problem.

Smoking is particularly relevant in the migraine with aura context. The interaction between smoking and migraine with aura for stroke risk is well-documented and pronounced. Men who smoke and have migraine with aura carry risks that are substantially higher than the sum of the individual contributions. For a man with migraine with aura who smokes, smoking cessation is among the highest-priority cardiovascular risk reductions available. The biological interaction likely operates through nicotine’s effects on platelet activation, vascular inflammation, and endothelial function, all of which are already activated in the migraine with aura phenotype.

Elevated LDL and dyslipidemia contribute to endothelial dysfunction and atherogenesis through pathways that converge with the endothelial changes observed in migraine with aura. Men with migraine with aura and LDL above 130 mg/dL, or with elevated non-HDL cholesterol, represent a population where lipid management directly addresses one of the compounding biological mechanisms identified in the migraine-vascular risk literature.

Physical inactivity matters in this context because aerobic fitness improves endothelial function, reduces vascular inflammation, and is associated with reduced migraine frequency in prospective studies. A man with migraine with aura who is sedentary carries more compounded cerebrovascular risk than the same man with regular aerobic activity. This is a modifiable input to a risk profile that already carries inherent elevation from the migraine diagnosis.

Atrial fibrillation, if present, produces an additional embolic risk source in a man already carrying the PFO-associated paradoxical embolism pathway described above. Undetected paroxysmal atrial fibrillation has been implicated in a meaningful fraction of cryptogenic stroke cases, and men with migraine with aura and any unexplained palpitations, exertional symptoms, or cardiac irregularity warrant rhythm evaluation as part of their vascular risk assessment.

What Clinical Evaluation Looks Like for Men With Migraine With Aura

The clinical approach to a man with migraine with aura in the context of cardiovascular risk assessment differs from the evaluation of migraine without aura, and it differs from the evaluation of a man whose migraine history has been noted but not incorporated into his cardiovascular risk profile. Several components are relevant.

A thorough blood pressure assessment is foundational. This means not relying on a single office reading but reviewing the pattern over time, including home readings and readings at different clinical encounters. Blood pressure variability across readings matters in the stroke risk context, not just the single-visit value. Men with migraine with aura and blood pressure consistently at or above 130 systolic are in a compounded risk zone that warrants explicit clinical discussion with their physician.

Lipid assessment in the context of migraine with aura should include attention to non-HDL cholesterol and LDL, and your cardiologist may discuss whether the migraine diagnosis shifts the threshold for initiating lipid-lowering therapy in the clinical conversation that incorporates your overall risk profile.

Cardiac rhythm evaluation is relevant for men with migraine with aura who have experienced cryptogenic stroke, unexplained neurological events, or symptoms that could represent paroxysmal atrial fibrillation. Extended rhythm monitoring is a tool your cardiologist may discuss, particularly if the standard ECG is unrevealing.

Echocardiography and specifically evaluation for PFO may be part of a workup your cardiologist recommends, particularly in younger men with migraine with aura who have experienced a first stroke or TIA without another identified mechanism. The clinical decision to pursue PFO evaluation is individualized and depends on the clinical context, not on the migraine diagnosis alone.

Neuroimaging, if not previously obtained, may be something your neurologist discusses in the context of documenting any subclinical white matter changes. This is a diagnostic discussion rather than a routine screening recommendation for all men with migraine, and the decision depends on symptoms, frequency, and clinical trajectory.

The migraine management itself, separate from the cardiovascular risk conversation, should be reviewed with a neurologist with expertise in headache medicine. The medications used for migraine prophylaxis and acute treatment have cardiovascular implications that your neurologist and cardiologist should ideally be aware of across your care.

How Men Should Think About This Risk

The productive framing for a man with migraine with aura is not alarm but context. The absolute stroke risk even at doubled relative risk remains low in young men without other compounding factors. The clinical value of the migraine with aura diagnosis in this conversation is that it elevates the priority of addressing every other modifiable risk factor in the cardiovascular profile: blood pressure, lipids, smoking, atrial fibrillation screening, physical activity, and weight management. These are the levers available, and they are more tractable than the migraine itself as intervention targets.

The less productive framing is to treat the migraine as a headache-department problem and leave the cardiovascular risk assessment unchanged. That framing is the one that leaves the forty-four-year-old man at the beginning of this article without a complete clinical picture. His migraine with aura history belongs in his cardiovascular chart. His cardiologist and his neurologist should have explicit coordination around his risk profile. His modifiable risk factors should be managed with the awareness that his baseline is not the same as a man who has never had an aura in his life.

Men who have been told they have migraine with aura and who have not had an explicit conversation with a cardiologist or internist about what that means for their cardiovascular risk assessment are carrying information their clinical team may not have fully processed. The conversation is worth initiating, and the question to ask is straightforward: given my migraine with aura history, how should this factor into my overall stroke and cardiovascular risk evaluation?

Frequently Asked Questions

Q: Does migraine with aura increase stroke risk in men the same way it does in women? A: The stroke risk elevation associated with migraine with aura is documented in both men and women. Some studies have shown the relative risk estimate to be somewhat higher in women, partly because the oral contraceptive interaction amplifies the risk substantially in women, creating a more visible signal in epidemiological data. However, prospective cohort data including the Physicians Health Study has confirmed that men with migraine with aura carry a significantly elevated risk of ischemic stroke and major cardiovascular events compared to men without migraine. The absolute risk in a young man without other risk factors remains low, but the relative elevation is real and clinically meaningful. Men should not assume that the stroke association applies only to women.

Q: Can treating migraines reduce the stroke risk? A: This is an important question that the evidence does not yet answer definitively. There are no large randomized trials demonstrating that effective migraine prophylaxis reduces the long-term stroke risk associated with migraine with aura. What the evidence does support is that reducing migraine frequency through preventive strategies may reduce the frequency of cortical spreading depression events and the associated vascular activation. The more directly supported approach is to aggressively manage all other modifiable stroke risk factors including blood pressure, smoking, lipids, and physical activity in men with migraine with aura, as these have demonstrated stroke risk reduction benefits in populations where the evidence base is robust. Your neurologist can discuss whether preventive migraine therapy is appropriate for your frequency and disability level.

Q: What is PFO and should I be tested for it? A: A patent foramen ovale is a small opening in the wall between the upper chambers of the heart that normally closes after birth. In about 25 to 30 percent of adults it remains open. Studies have found higher rates of PFO in people with migraine with aura compared to the general population, and in men who have had a cryptogenic stroke, a PFO provides a potential mechanism for paradoxical embolism. Whether routine testing for PFO is appropriate depends on your clinical history. Men with migraine with aura who have not had a stroke or TIA are generally not routinely evaluated for PFO based on the migraine diagnosis alone. Men who have had an unexplained stroke or TIA should discuss PFO evaluation with their cardiologist, as the combination of migraine with aura and PFO may be relevant to understanding the stroke mechanism and to subsequent management decisions.

Q: Are triptans or other migraine medications safe for men with stroke risk? A: This question belongs in a direct conversation with your physician and neurologist. Triptans are vasoconstrictive medications that are generally avoided in men with established coronary artery disease, prior stroke or TIA, uncontrolled hypertension, or significant peripheral vascular disease. For a man with migraine with aura and no other established vascular disease, the risk-benefit calculation is individualized and depends on the severity of the migraine, the frequency of attacks, the availability of alternatives, and the overall cardiovascular risk profile. Your neurologist and cardiologist should ideally discuss your acute and preventive migraine management together with awareness of your full cardiovascular risk picture.

Q: Is migraine with aura the same as TIA, and how can I tell the difference? A: Migraine aura and transient ischemic attack can be difficult to distinguish clinically, and this distinction is important because TIA requires urgent evaluation. Visual aura from migraine typically develops gradually over 5 to 30 minutes, progresses in a characteristic spreading pattern, and resolves within 60 minutes. The zigzag scintillating scotoma is highly characteristic of migraine aura and is rarely seen with TIA. By contrast, the visual disturbance of a TIA tends to be abrupt in onset, often described as a curtain or shade coming down over part of the visual field, without the gradual spreading quality. Motor or sensory aura that is unfamiliar in character, longer than 60 minutes, or accompanied by headache that is qualitatively different from prior migraines warrants urgent medical evaluation rather than the assumption that it represents a typical migraine episode. When in doubt, err toward urgent evaluation rather than watchful waiting.